- Conditions
- NK-Cell Lymphoma, NK-Cell Leukemia, Peripheral T Cell Lymphoma
- Interventions
- Methotrexate, pralatraxate,, Ifosfamide, Dexamethasone, Etoposide, calaspargase pegol, cyclophosphamide, Doxorubicin, Prednisone, Brentuximab Vedotin
- Drug
- Lead sponsor
- New York Medical College
- Other
- Eligibility
- 1 Year to 31 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Orange, California • San Francisco, California + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 673–696
of 8,003
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Prostate Cancer, Liver Cancer, Breast Cancer, Colon Cancer, Lung Cancer
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 750 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Interventions
- filgrastim, cytarabine, bismuth Bi213 monoclonal antibody M195
- Biological · Drug · Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Up to 120 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Endometrial Cancer
- Interventions
- OK-1 & Paclitaxel
- Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Sickle Cell Disease
- Interventions
- Aes-103, Placebo
- Drug
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Advanced Breast Cancer
- Interventions
- HKI-272, trastuzumab
- Drug
- Lead sponsor
- Puma Biotechnology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2018
- U.S. locations
- 6
- States / cities
- Duarte, California • Los Angeles, California • Pasadena, California + 3 more
- Conditions
- Highly Sensitized Prospective Kidney Transplant Recipients
- Interventions
- carfilzomib, belatacept, Bone marrow aspiration
- Biological · Procedure
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Typhoid and Paratyphoid Fevers
- Interventions
- Ty800, Placebo
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Lower Extremity Injury
- Interventions
- Platelet Poor Plasma (PPP) Injection
- Device
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 3
- States / cities
- Englewood, Colorado • Atlanta, Georgia • Iowa City, Iowa
- Conditions
- MASH - Metabolic Dysfunction-Associated Steatohepatitis
- Interventions
- Resmetirom, Placebo
- Drug
- Lead sponsor
- Madrigal Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 16
- States / cities
- La Jolla, California • Los Angeles, California • San Francisco, California + 12 more
- Conditions
- Full Aniridia, Partial Aniridia
- Interventions
- Artificial Iris (CustomFlex)
- Device
- Lead sponsor
- Clinical Research Consultants, Inc.
- Industry
- Eligibility
- 3 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2025
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Atlanta, Georgia • Indianapolis, Indiana + 8 more
- Conditions
- Diabetes Mellitus, Obesity
- Interventions
- Trodusquemine (MSI-1436)
- Drug
- Lead sponsor
- Genaera Corporation
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Healthy Elderly
- Interventions
- PF-06743649, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 65 Years to 85 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 2
- States / cities
- South Miami, Florida
- Conditions
- Aortic Aneurysm, Abdominal, Thoracic Aneurysm
- Interventions
- Fenestrated CMD, Type I - III TAAA, Arch cohort
- Device
- Lead sponsor
- Carlos Timaran
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2028
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Dallas, Texas
- Conditions
- Blepharospasm of Both Eyelids, Blepharospasm of Left Eyelid, Blepharospasm of Right Eyelid, Blepharospasm, Benign Essential, Blepharospasm
- Interventions
- Botulinum Neurotoxin Type A
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Bladder Cancer
- Interventions
- Pembrolizumab, Intismeran autogene, Placebo, Enfortumab Vedotin, Surgery (RC plus PLND)
- Biological · Other · Procedure
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Orlando, Florida • Chicago, Illinois + 7 more
- Conditions
- Unresectable Stage III, Stage IV Melanoma
- Interventions
- Lenvatinib
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 79
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 76 more
- Conditions
- Colorectal Neoplasm, Colorectal Cancer
- Interventions
- Imatinib mesylate and panitumumab, Standard-of-care treatment with panitumumab
- Drug
- Lead sponsor
- Inova Health Care Services
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 2
- States / cities
- Fairfax, Virginia • Falls Church, Virginia
- Conditions
- Achondroplasia
- Interventions
- Infigratinib 0.016 mg/kg, Infigratinib 0.032 mg/kg, Infigratinib 0.064 mg/kg, Infigratinib 0.128 mg/kg, Infigratinib 0.25 mg/kg
- Drug
- Lead sponsor
- QED Therapeutics, a BridgeBio company
- Industry
- Eligibility
- 3 Years to 11 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 5
- States / cities
- Oakland, California • Wilmington, Delaware • Baltimore, Maryland + 2 more
- Conditions
- Solid Tumor, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma
- Interventions
- GEN-001, Avelumab
- Drug
- Lead sponsor
- Genome & Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 3
- States / cities
- New Haven, Connecticut • Atlanta, Georgia • Portland, Oregon
- Conditions
- Steroid Refractory GVHD, Graft Vs Host Disease
- Interventions
- Itacitinib, Tocilizumab
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Perianal Warts
- Interventions
- Leukocyte Interleukin, Injection
- Biological
- Lead sponsor
- CEL-SCI Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 2
- States / cities
- San Diego, California • San Francisco, California
- Conditions
- Heart Failure and Reduced Ejection Fraction, Functional Mitral Regurgitation
- Interventions
- Cardiac MRI
- Diagnostic Test
- Lead sponsor
- Minneapolis Heart Institute Foundation
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 5
- States / cities
- Minneapolis, Minnesota • Charlotte, North Carolina • Cincinnati, Ohio + 2 more
- Conditions
- Endometrial Cancer
- Interventions
- Hypofractionated WPRT
- Radiation
- Lead sponsor
- Teresa Meier
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio